RayKnowChina Research Map
Shortlist

RecruitingLymphomaPhase 2

Registered title, quoted from ClinicalTrials.gov

Zanubrutinib, Obinutuzumab Combined With Lenalidomide (ZGR) for the Treatment of Untreated Follicular Lymphoma

An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorInstitute of Hematology & Blood Diseases Hospital, CAMS & PUMC中国医学科学院血液病医院(血液学研究所)TianjinHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07299149, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 7

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (7 points)Hide the checklist
  1. 18 years to 90 years; sex: all

    Registered eligibility fields

  2. Contraception: Men and women of childbearing potential must agree to use highly effective contraception during the study and for 4 weeks after treatment discontinuation.

    Inclusion criterion 22

  3. ECOG Performance Status: ≤2.

    Inclusion criterion 13

  4. e) Cytopenias due to bone marrow infiltration (hemoglobin <10 g/dL, absolute neutrophil count [ANC] <1.0×10⁹/L, platelets <100×10⁹/L).

    Inclusion criterion 9

    a) ANC ≥1.0×10⁹/L (without growth factor support).

    Inclusion criterion 17

    b) Platelets ≥50×10⁹/L (untransfused within 7 days).

    Inclusion criterion 18

    c) Total bilirubin (TBIL) ≤1.5×ULN.

    Inclusion criterion 19

    d) ALT/AST ≤3×ULN.

    Inclusion criterion 20

    e) Creatinine clearance ≥30 mL/min (calculated by modified Cockcroft-Gault formula).

    Inclusion criterion 21

  5. Measurable Disease: At least one measurable lesion (>2 cm in longest diameter by CT/MRI).

    Inclusion criterion 14

  6. Prior history of malignancy, unless the patient has been disease-free for ≥5 years and the treating physician deems the risk of recurrence low (exceptions: non-melanoma skin cancer, cured localized prostate cancer, carcinoma in situ of the cervix, or squamous intraepithelial lesions on PAP smear).

    Exclusion criterion 5

    HIV, active hepatitis B/C infection (HBV DNA ≥2000 IU/mL or HCV RNA detectable)

    Exclusion criterion 14

  7. Pregnancy, lactation, or unwillingness to use effective contraception in women of childbearing potential.

    Exclusion criterion 18

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07299149, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Gender: No restrictions; age ≥18 years.
  • Diagnosis: Histologically confirmed CD20-positive follicular lymphoma (FL), Grade 1, 2, or 3A, per 2016 WHO classification. All patients must provide sufficient archived or fresh tumor tissue samples for immunohistochemical (IHC) analysis.
  • Disease Stage \& Treatment Need:
  • Stage III or IV disease, or Stage II with bulky disease, meeting at least one of the following criteria:
  • a) Bulky disease: Lymph node or extranodal (excluding spleen) mass with maximum diameter ≥7 cm.
  • b) Local symptoms or organ dysfunction due to progressive lymphadenopathy or extranodal tumor mass.
  • c) B symptoms (fever, night sweats, or unintentional weight loss >10% of body weight within ≤6 months).
  • d) Symptomatic extranodal involvement (e.g., pleural/peritoneal effusion).
  • e) Cytopenias due to bone marrow infiltration (hemoglobin <10 g/dL, absolute neutrophil count [ANC] <1.0×10⁹/L, platelets <100×10⁹/L).
  • f) Involvement of ≥3 lymph nodes, each ≥3 cm in diameter.
  • g) Symptomatic splenomegaly.
  • Prior Therapy: No prior systemic therapy for FL.
  • ECOG Performance Status: ≤2.
  • Measurable Disease: At least one measurable lesion (>2 cm in longest diameter by CT/MRI).
  • Life Expectancy: ≥6 months.
  • Adequate Organ Function:
  • a) ANC ≥1.0×10⁹/L (without growth factor support).
  • b) Platelets ≥50×10⁹/L (untransfused within 7 days).
  • c) Total bilirubin (TBIL) ≤1.5×ULN.
  • d) ALT/AST ≤3×ULN.
  • e) Creatinine clearance ≥30 mL/min (calculated by modified Cockcroft-Gault formula).
  • Contraception: Men and women of childbearing potential must agree to use highly effective contraception during the study and for 4 weeks after treatment discontinuation.
  • Informed Consent: Patients must voluntarily participate and sign informed consent forms (ICF).

Exclusion Criteria:

  • Patients meeting any of the following criteria will be excluded from this study:
  • Histologic evidence of central nervous system (CNS) lymphoma, leptomeningeal lymphoma, or transformation to high-grade lymphoma (e.g., diffuse large B-cell lymphoma, DLBCL).
  • Grade 3B follicular lymphoma (FL) or transformed FL.
  • Ann Arbor Stage I FL.
  • Prior history of malignancy, unless the patient has been disease-free for ≥5 years and the treating physician deems the risk of recurrence low (exceptions: non-melanoma skin cancer, cured localized prostate cancer, carcinoma in situ of the cervix, or squamous intraepithelial lesions on PAP smear).
  • Use of any investigational drugs, antibiotics, or participation in another interventional clinical trial within 4 weeks prior to enrollment.
  • Major surgery (excluding lymph node biopsy) within 14 days before enrollment or anticipated need for major surgery during the study.
  • Prior treatment with zanubrutinib, obinutuzumab, or lenalidomide.
  • Immunodeficiency or autoimmune disease history, or chronic systemic steroid therapy (>10 mg/day prednisone equivalent) or immunosuppressive therapy within 7 days before enrollment.
  • Severe hepatic dysfunction (including severe jaundice, hepatic encephalopathy, refractory ascites, or hepatorenal syndrome), cachexia, or multi-organ failure with renal impairment.
  • Clinically significant cardiovascular abnormalities:
  • NYHA Class III/IV heart failure
  • Myocardial infarction within 6 months before enrollment, Malignant arrhythmias (including QTc ≥480 ms), Uncontrolled hypertension (Systolic blood pressure (SBP) ≥150 mmHg and diastolic blood pressure (DBP) ≥100 mmHg), Unstable angina.

Active infections:

  • HIV, active hepatitis B/C infection (HBV DNA ≥2000 IU/mL or HCV RNA detectable)
  • Uncontrolled systemic infections.
  • Bleeding disorders or coagulation abnormalities, or thrombotic events within 3 months.
  • Severe hypersensitivity to the active ingredients or excipients of the study drugs.
  • Pregnancy, lactation, or unwillingness to use effective contraception in women of childbearing potential.
  • Other conditions deemed unsuitable by the investigator.

Quoted from ClinicalTrials.gov, NCT07299149, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07299149, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07299149